계정 가입
email 로 로그인
email 로 가입
수신함을 확인하세요
Kanaph Therapeutics
About
Kanaph Therapeutics is a leading biotech in oncology, auto-immune, and eye diseases with large molecules and small molecules.
- 11 - 50
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $21M
- Industries
- Biotechnology,Life Science,Pharmaceutical
- Founded date
- Feb 14, 2019
- Number Of Employee
- 11 - 50
- Operating Status
- Active
Kanaph Therapeutics is a biotech with activities that range from drug discovery to early-stage clinical trials. We are dedicated to developing next-generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor microenvironment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 12, 2020 | Series B | $21M | 1 | — | — | Detail |
| Oct 22, 2019 | Series A | $6M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
|
— | Series B |
